News und Analysen
DGAP-News: EVOTEC AND BIOASTER PARTNER TO BUILD A TECHNOLOGY AND INNOVATION HUB IN LYON
DGAP-News: EVOTEC AND BIOASTER PARTNER TO BUILD A TECHNOLOGY AND INNOVATION HUB IN LYON
DGAP-News: Abivax gibt 2-Jahres-Daten zur Langzeitwirkung und Sicherheit aus der Phase-2a-Erhaltungsstudie mit ABX464 zur Behandlung von Colitis ulcerosa bekannt
DGAP-News: Abivax gibt 2-Jahres-Daten zur Langzeitwirkung und Sicherheit aus der Phase-2a-Erhaltungsstudie mit ABX464 zur Behandlung von Colitis ulcerosa bekannt
DGAP-News: ABIVAX: Abivax reports long-lasting two-year efficacy and safety data from ABX464 ulcerative colitis Phase 2a maintenance study
DGAP-News: ABIVAX: Abivax reports long-lasting two-year efficacy and safety data from ABX464 ulcerative colitis Phase 2a maintenance study
DGAP-News: EVOTEC ERWEITERT IHRE PROPRIETÄRE PATIENTENDATENBANK IN DEN BEREICH LEBERERKRANKUNGEN DURCH EINZIGARTIGEN ZUGANG ZUR QUOD BIOBANK
DGAP-News: EVOTEC ERWEITERT IHRE PROPRIETÄRE PATIENTENDATENBANK IN DEN BEREICH LEBERERKRANKUNGEN DURCH EINZIGARTIGEN ZUGANG ZUR QUOD BIOBANK
DGAP-News: EVOTEC EXPANDS ITS PROPRIETARY PATIENT DATABASE INTO LIVER DISEASE WITH UNIQUE ACCESS TO QUOD BIOBANK
DGAP-News: EVOTEC EXPANDS ITS PROPRIETARY PATIENT DATABASE INTO LIVER DISEASE WITH UNIQUE ACCESS TO QUOD BIOBANK
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
DGAP-News: Eckert & Ziegler Receives Approval for Gallium-68 Generator for Canada
DGAP-News: Eckert & Ziegler Receives Approval for Gallium-68 Generator for Canada
DGAP-News: Eckert & Ziegler: Gallium-68-Generator erhält Zulassung für Kanada
DGAP-News: Eckert & Ziegler: Gallium-68-Generator erhält Zulassung für Kanada
DGAP-News: Eckert & Ziegler: Gallium-68-Generator erhält Zulassung für Kanada
DGAP-News: Eckert & Ziegler: Gallium-68-Generator erhält Zulassung für Kanada
DGAP-News: Eckert & Ziegler Receives Approval for Gallium-68 Generator for Canada
DGAP-News: Eckert & Ziegler Receives Approval for Gallium-68 Generator for Canada
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion
DGAP-Adhoc: Takeda Pharmaceutical Company Limited: Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion
DGAP-Adhoc: QIAGEN N.V.: Resignation of Chairman of the Supervisory Board
DGAP-Adhoc: QIAGEN N.V.: Resignation of Chairman of the Supervisory Board
DGAP-Adhoc: QIAGEN N.V.: Resignation of Chairman of the Supervisory Board
DGAP-Adhoc: QIAGEN N.V.: Resignation of Chairman of the Supervisory Board
DGAP-Adhoc: QIAGEN N.V.: Rücktritt des Aufsichtsratsvorsitzenden
DGAP-Adhoc: QIAGEN N.V.: Rücktritt des Aufsichtsratsvorsitzenden
DGAP-Adhoc: QIAGEN N.V.: Rücktritt des Aufsichtsratsvorsitzenden
DGAP-Adhoc: QIAGEN N.V.: Rücktritt des Aufsichtsratsvorsitzenden
DGAP-News: EVOTEC UND CENTOGENE ERWEITERN ZUSAMMENARBEIT UM GAUCHER-KRANKHEIT
DGAP-News: EVOTEC UND CENTOGENE ERWEITERN ZUSAMMENARBEIT UM GAUCHER-KRANKHEIT
DGAP-News: EVOTEC AND CENTOGENE EXPAND COLLABORATION INTO GAUCHER DISEASE
DGAP-News: EVOTEC AND CENTOGENE EXPAND COLLABORATION INTO GAUCHER DISEASE
DGAP-News: US-amerikanisches National Comprehensive Cancer Network(R) nimmt Monjuvi(R) (Tafasitamab-cxix) in seine Leitlinien für die klinische Praxis in der Onkologie für B-Zell-Lymphome auf
DGAP-News: US-amerikanisches National Comprehensive Cancer Network(R) nimmt Monjuvi(R) (Tafasitamab-cxix) in seine Leitlinien für die klinische Praxis in der Onkologie für B-Zell-Lymphome auf
DGAP-News: National Comprehensive Cancer Network(R) Adds Monjuvi(R) (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
DGAP-News: National Comprehensive Cancer Network(R) Adds Monjuvi(R) (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
DGAP-News: National Comprehensive Cancer Network(R) Adds Monjuvi(R) (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
DGAP-News: National Comprehensive Cancer Network(R) Adds Monjuvi(R) (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for B-cell Lymphomas